-
1. Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts. Blood (Journal of The American Society of Hematology), 97: 2524 (2001) 16.6
Tamayose K, Ando M, Oshimi K, et al.
-
2. Secondary myelodysplasticsyndrome after treatment of prostate cancer with oral estramustine. American Journal of Hematology (Wiley). 67: 274-275 (2001) 6.13
Ando M, Tamayose K, Oshimi K, et al.
-
3. Selective apoptosis of natural killer-cell tumours by l-asparaginase. British Journal of Haematology (Wiley) 130: 860-868 (2005) 5.2
Ando M, Sugimoto K, Oshimi K, et al.
-
4. Spindle checkpoint protein Bub1 corrects mitotic aberrancy induced by human T-cell leukemia virus type I Tax. Oncogene 25(26):3621-7(2006) 6.8
Sasaki M, Ando M, Oshimi K, et al.
-
5. Changes in cell morphology and cytoskeletal organization are induced by human mitotic checkpoint gene, Bub1. Biochemical and Biophysical Research Communications, Elsevier, 365:691-697 (2008)
Ando J, Ando M, Oshimi K, et al.
-
6. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene 27(22):3091-101 (2008)
Sugimoto K, Ando M, Oshimi K, et al.
-
7. CD20-positive extranodal NK-cell lymphoma, nasal-type. European Journal of Haematology, (Wiley) 80: 549-550 (2008)
Ando J, Ando M, Oshimi K, et al.
-
8. Bortezomib sensitizes non small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity Cancer Gene Therapy, 21(11):472-82, 2014
Ando M, Valentina Hoyos, Lisa Bouchier-Hayes, et al.
-
9. Mesenchymal stromal cells for linked delivery of oncolytic and apoptotic adenoviruses to non-small cell lung cancers. Molecular Therapy, 23(9):1497-506, 2015
Valentina Hoyos, Francesca Del Bufalo, Ando M, et al.
-
10. A Safeguard System for Induced Pluripotent Stem-Cell Derived Rejuvenated T-cell Therapy. Stem Cell Reports, 5(4):597-608, 2015
Ando M, Nishimura T, Nakauchi H, et al.
-
11. “Off-the-shelf” Immunotherapy with iPSC-Derived Rejuvenated Cytotoxic T Lymphocytes. Experimental Hematology, Mar;47:2-12, 2017
Ando M and Nakauchi H.
-
12. Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives Stem Cell Reports, 8(3):673-684, 2017
Itakura G, Ando M, Okano H, et al.
-
13. Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of Sjögren's Syndrome. Stem Cell Reports, 8(5):1155-1163, 2017
Iizuka-Koga M, Ando M, Sumida T, et al.
-
14. iPSC-derived rejuvenated T-cell therapy for Epstein-Barr virus-associated lymphomas. Rinsho Ketsueki (Japanese Society of Hematology),59(7): 932-938, 2018
Ando M, Nakauchi H and Komatsu N.
-
15. Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by iPSC-derived Epstein-Barr virus - specific rejuvenated T cells in vivo. Haematologica, volume 105(3): 796-807, 2020, Doi:10.3324/haematol.2019.223511
Ando M, Ando J, Komatsu N, et al.
-
16. : Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy, 22(11) 642-652, 2020
Ando J, Ando M, Cliona M. Rooney, et al.
-
17. iPSC-derived rejuvenated T cell therapy for Extranodal NK/T-cell lymphoma, nasal type. Juntendo Medical Journal, 66(3), 200-205, 2020
Ando M, Ando J, Komatsu N, et al.
-
18. Sustainable tumor suppressive effect of iPSC-derived rejuvenated T cells targeting cervical cancers. Molecular Therapy, 28(11), 2394-2405, 2020
Honda T, Ando M, Komatsu N, et al.
-
19. Persistent immune thrombocytopaenic purpura associated with SARS-Cov-2 infection. eJHaem, 2(3), 530-533, 2021
Furukawa Y, Ando M, Ando J, et al.
-
20. High-grade primary central nervous system lymphomatoid granulomatosis: Successfully rituximab monotherapy. Internal Medicine, 60(23), 3795-3799, 2021
Harada S, Ando M, Komatsu N, et al.
-
21. Primary lymphoma of the pericardium. Internal Medicine, 60(24), 4005-4006, 2021
Kinoshita S, Ando M, Komatsu N, et al.
-
22. Sarcoma-like appearance but pathologic Hodgkin lymphoma. International Journal of Hematology, 114:1-2, 2021
Harada S, Ando M, Komatsu N, et al.
-
23. iPSC-derived neoantigen-specific cytotoxic T lymphocyte therapy for Ewing sarcoma, Cancer Immunology Research, 9(10), 1175-1186, 2021
Ishii M, Ando J, Ando M, et al.
-
24. SCLC-J1, a novel small cell lung cancer cell line. Biochemistry and Biophysics Reports, 27, 101089, 2021
Ohara K, Kinoshita S, Ando M, et al.
-
25. Trigenic ADH5 / ALDH2 / ADGRV1 mutations in myelodysplasia with Usher syndrome. Heliyon, 7(8), e07804, 2021
Kinoshita S, Ando M, Komatsu N, et al.
-
26. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphomas. Molecular Therapy, 30 (2), 534-549, 2022
Harada S, Ando M, Komatsu N, et al.
-
27. Advances in allogeneic cancer cell therapy and future perspectives on “off-the-shelf” T cell therapy using iPSC technology and gene editing. Cells, 11, 269, 2022
Furukawa Y, Hamano Y, Ando M, et al.
-
28. Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations. Clinical Lymphoma, Myeloma and Leukemia, July 2022
Yasuda H, Komatsu N, Ando M, et al.
-
29. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology, Sep 2023
Yasuda H, Taka H, Ando M, et al.
-
30. Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients. British Journal of Haematology, Oct 2023
Furuya C, Ando M, Komatsu N, et al.
-
31. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer. Cell Reports Medicine, Nov 2023; 4(12): 101327. doi: 10.1016. IF 16.988 (2022)
Furukawa Y, Ishii M, Ando M, et al.
-
32. Establishment of ganglioside GD2-expressing extranodal NK/T cell lymphoma cell line with scRNA-seq analysis. Experimental Hematology, Nov 2023;S0301-472X(23)01769-1. doi: 10.1016.
Sato S, Ishii M, Ando M, et al.
-
33. Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia. Heliyon. Jan 2024 (IF: 4.0)
Uchimura A, Yasuda H, Ando M, et al.
-
34. Rejuvenated iPSC-derived GD2-directed CART cells harbor robust cytotoxicity against small cell lung cancer. Cancer Research Communications. Jan 2024 4(3): 723-737
Kinoshita S, Ishii M, Ando M, et al.
-
35. L-asparaginase monotherapy as an encouraging approach towards acute fulminant chronic active Epstein-Barr virus infection. British Journal of Haematology(IF: 5.1) July 2024
Furukawa Y, Ando J, Ando M, et al.
-
36. Eleven cases of laryngeal edema after tisagenlecleucel infusion: A 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas. Haematologica, Oct 2024 (IF: 8.2)
Hosoya E, Ando J, Ando M, et al.